Filing summary
Entity note: The request identifies Leonabio, Inc., but the supplied Form 10-Q is for Athira Pharma, Inc. (Nasdaq: ATHA). This summary reflects the filing provided, not Leonabio.
Business context and reporting period
Athira is a late clinical-stage biopharmaceutical company developing small molecules for neurodegenerative disorders. The unaudited quarter ended March 31, 2023, compared with the three months ended March 31, 2022. The company has no approved products and has not generated product revenue.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $21.3 million | $14.5 million; up 47% |
| General and administrative expense | $8.5 million | $8.9 million; down 5% |
| Total operating expenses | $29.8 million | $23.4 million; up 27% |
| Grant income | $0.2 million | $2.2 million |
| Other income, net | $1.8 million | $0.2 million |
| Net loss | $27.8 million | $21.0 million |
| Basic and diluted loss per share | $0.73 | $0.56 |
| Cash used in operating activities | $26.2 million | $16.6 million |
Research and development spending rose primarily from fosgonimeton trial activity, open-label extensions, increased personnel costs, and preclinical work. Grant income declined because the NIH grant had reached its approved $15.2 million total by March 31, 2023; no further income is expected under that grant. Higher interest and investment-discount accretion contributed to increased other income. Profit margins are not meaningful for this pre-revenue company.
At March 31, 2023, cash and cash equivalents were $105.2 million, short-term investments $80.8 million, and long-term investments $33.9 million: approximately $219.9 million in cash, cash equivalents and investments, versus approximately $245.2 million at December 31, 2022. The company reported a $219.4 million accumulated deficit and $211.1 million in stockholders’ equity. It stated that current resources should fund operating expenses and capital expenditures for at least 12 months following the May 11, 2023 filing date.
The company reported no conventional borrowings in the presented balance sheet; operating lease liabilities totaled $1.8 million, with $0.3 million current. Lease payments are approximately $2.2 million undiscounted, including $0.5 million due within 12 months. An at-the-market equity program permits up to $75 million of sales, but no shares had been sold under it as of the filing.
Material changes, outlook and key developments
- Operating cash use increased by $9.6 million year over year, reflecting the larger net loss. Investing cash inflow mainly reflected maturities of available-for-sale securities; financing cash inflow was limited to stock-option exercises.
- ACT-AD’s primary and secondary endpoints were not met under the planned analyses. A post hoc, prespecified subgroup analysis suggested possible benefit among participants not taking background acetylcholinesterase inhibitors, but results were not statistically significant.
- Following an interim analysis, an independent monitoring committee recommended continuing the LIFT-AD Phase 2/3 trial. In May 2023, after quarter-end, Athira amended the trial to focus on the 40 mg dose and stop enrolling the 70 mg arm. The company said timing would be updated after its planned FDA end-of-Phase-2 meeting.
- Athira planned to extend the open-label extension study, potentially allowing eligible participants up to 30 months of open-label treatment and collection of up to 36 months of total long-term exposure data.
- Management expects losses and expenses to continue, particularly as clinical development, staffing, manufacturing preparation, legal costs, and public-company costs continue. Additional funding will be required; financing may dilute shareholders or impose other unfavorable terms.
- A proposed $10 million securities-class-action settlement was accrued in 2022 and remained subject to court approval. Separate shareholder derivative cases were stayed. The DOJ had issued a Civil Investigative Demand and the SEC a subpoena; Athira said it was cooperating, but could not predict outcomes. The company said other potential losses could not be reasonably estimated.
- A board special committee found that the former CEO altered images in her dissertation and at least four research papers, that the company had cited challenged papers in certain materials, and that the WSU dihexa patent licensed to Athira incorporated some altered images. WSU’s review remained ongoing. The filing warns of potential impacts to reputation, licensing, grants, and intellectual property.
Most important facts for investors to verify
- Confirm the filing issuer: the supplied document is Athira Pharma, not Leonabio.
- Track LIFT-AD enrollment, the 40 mg trial design, FDA feedback, endpoints, and eventual results; distinguish prespecified analyses from post hoc findings.
- Assess the $219.9 million liquidity balance against the rising quarterly operating cash burn and the stated 12-month runway assumption.
- Check court approval and funding of the proposed $10 million settlement, and developments in the DOJ, SEC, WSU, and derivative proceedings.
- Monitor whether the WSU review affects the licensed dihexa intellectual property, NIH-related matters, or future development plans.
- Verify any future ATM sales and resulting dilution; no ATM shares had been sold as of the filing.